Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized, double-blind, placebo-controlled study of BI 409306 in schizophrenia
2017-002369-23Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of osoresnontrine in schizophrenia (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first relapse until study end. Started Apr 2019; status: terminated.
02
Drugs
osoresnontrine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-002369-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002369-23.